Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma (Q83139511)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

Erb-b2 receptor tyrosine kinase 2

19 January 2020

main subject

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Harri Sihto

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Heikki Joensuu

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

5

Jorma Isola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

6

Nina N Nupponen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

7

Ralf Butzow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Arto Leminen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

11 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

Journal of Molecular Medicine

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

671-681

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16607561%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00109-006-0054-4

19 January 2020

exact match

0 references

cites work

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

1 reference

12 December 2020

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

12 December 2020

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

1 reference

12 December 2020

Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line.

1 reference

12 December 2020

Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence

1 reference

12 December 2020

Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

1 reference

12 December 2020

Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation

1 reference

12 December 2020

Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization

1 reference

12 December 2020

Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.

1 reference

12 December 2020

Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas

1 reference

12 December 2020

High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo

1 reference

12 December 2020

ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma

1 reference

12 December 2020

Treatment of ovarian cancer: new strategies

1 reference

12 December 2020

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

12 December 2020

Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study

1 reference

12 December 2020

A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging

1 reference

12 December 2020

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

1 reference

12 December 2020

Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

12 December 2020

Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer

1 reference

12 December 2020

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

1 reference

12 December 2020

Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells

1 reference

12 December 2020

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

12 December 2020

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

1 reference

12 December 2020

Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors

1 reference

12 December 2020

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

12 December 2020

Structural alterations of the epidermal growth factor receptor gene in human gliomas

1 reference

12 December 2020

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

12 December 2020

Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage

1 reference

12 December 2020

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

1 reference

12 December 2020

Distinct subtypes of serous ovarian carcinoma identified by p53 determination

1 reference

12 December 2020